Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
AA

NASDAQ · AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

Healthcare · Biotechnology

$13.48

Up+$1.40 (+10.35%)

Updated Nov 4, 2026, 5:28 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.23B
P/E ratio
-12.12
Dividend yield
0.00%
52-week range
$13.46 – $35.49
Volume
1.82K
Avg. volume
3.2K

Price performance · AAPG

AAPG price history

1M range · 0 trading sessions · Daily adjusted prices

AAPG does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest AAPG news

The latest Smart Investors Daily articles mentioning AAPG.

Stock researchCompany · Overview

AAPG research

Overview

Company profile and research snapshot.

Company profile

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$48.00
Implied upside
—
Analysts
13
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 20, 2026

Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL

ROCKVILLE, Md., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced today that lisaftoclax (APG-2575), the Company’s novel Bcl-2 inhibitor, has been granted a Breakthrough Therapy Designation (BTD) by the Center for Drug Evaluation (CDE) of

Yahoo · Oct 19, 2026

Ascentage Pharma (SEHK:6855) Stock Looks Above Fair Value After The Fall

Ascentage Pharma Group International has seen its share price move sharply in recent years, yet the current level still leaves a straightforward question for investors who care about fundamentals. Is the price you see on screen today reasonably aligned with what the business is generating in sales, or has sentiment moved further than the top line can comfortably support? With the stock down 56.4% over the past year, the slide puts fresh focus on whether the present valuation can still be...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By